Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms.
All News
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
A 46-year-old with psoriatic arthritis and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Switch class, optimize methotrexate, or ask whether the dose itself is too low?
We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting our ability to treat them effectively.
IL-23 therapies are among the most efficacious and safest treatment options for patients with skin psoriasis. The enthusiasm for IL-23 agents for PsA is perhaps more tempered; while efficacy has been demonstrated for peripheral joint disease, there is concern that these agents are not effective in patients with axial disease.
Tsao et al presented abstract #2773 consensus recommendations for CAR-T cell therapy in the SARDs from the Taiwan College of Rheumatology. They are thorough and outline a sensible approach.
Ab#2804 #ACR26 @RheumNow BE BOLD: Bimekiz v Risankiz in PsA, 24w H2H P3B W16 (primary endpt): ACR50: BKZ 49% v 38% RZB, p=.006, W24: 56% v 44% MDA, ACR50+PASI100 NOT signif PASI100: BKZ earlier, equal later BKZ - better for jts, earlier skin but equal later, more Candida #ACRBest https://t.co/q6g6zQMutY
Stromal CAR-T: target is the FAPa+ synovial fibroblast Mouse arthritis, CAR-T IV at 1st flare Swelling AUC lower over 3 episodes, all p<0.001 Lining architecture restored Preclinical. FAPa sits outside the joint, off-target depletion decides the path Adam Croft @RheumNow #ACR26 https://t.co/vufSwu4gKU
